KoBioLabs

At a glance

KoBioLabs filed 16 disclosures in the last 12 months.

Revenue for 2025 was ₩69.3B, up 1.4% on 2024. It made an operating loss of ₩9.7B. Debt was 85% of equity at year end. The latest interim report (2026 H1) shows revenue of ₩41B and operating loss of ₩4.7B.

The 2025 annual report lists 57 employees with an average tenure of 3.7 years and average pay of ₩57.8M, #1082 of 1,829 listed companies by average pay. Its 6 directors and auditors were paid ₩122.6M each on average. It paid no cash dividend for 2025. 고광표 and related parties held 29.83% at year end.

From the 2025 annual report

Staff: 57 (26 men, 31 women), of whom 2 on fixed-term contracts. Total pay for the year: ₩3.3B. Directors and auditors: 6, paid ₩735.9M in total.

No cash dividend was paid for 2025.

Largest shareholder

고광표 holds 25.70%; with 11 related parties the group holds 29.83% of common shares at year end (from 29.87% at the start of the year).

Auditor: 삼정회계법인 · opinion: Unqualified.

Source: 2025 annual business report (DART). How figures are combined

Financial summary